이수앱지스

086890KOSDAQ의료용품 및 기타 의약 관련제품 제조업

46.5 / 100

Reference Date: 2026-04-13

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but Revenue metrics are weak. Declined 8.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Isu Appgis primarily operates in the pharmaceutical sector, focusing on key products such as Absorcin (for Gaucher disease), Fabrazyme (for Fabry disease), and Clotyplast (an antibody therapy for cardiovascular conditions). In 2024, sales reached 60.3 billion won, a 11% increase from the previous year, with product sales accounting for 86.3% of total revenue. Product prices have remained stable over the past three years.

Number of Employees

190people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 19.894.0Point

PBR

1.65Industry Average 1.622.5Point

Higher than industry avg (caution)

ROE

-9.92Industry Average -4.893.5Point

2.0x industry avg (excellent)

Debt Ratio

6.96Industry Average 8.884.0Point

In line with industry avg

Trend 2023~20255.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲2.5% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲78.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.9% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 1Neutral 0Negative 1Average Sentiment Score 50

Positive
이수앱지스, 고셔병 치료제 ‘애브서틴’ 이집트 공급 계약…중동·북...
이수앱지스는 이집트 희귀질환 치료제 전문 기업과 고셔병 치료제 '애브서틴' 공급 계약을 체결하여 중동·북아프리카(MENA) 시장 확장을 가속화하고 있습니다.
Negative
식약처, 이수앱지스에 일부 임상시험 1개월 업무정지
식품의약품안전처가 이수앱지스에 일부 임상시험 관련 법령 위반으로 해당 임상시험 업무정지 1개월 처분을 내려 단기적인 부정적 영향이 예상됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (12%, downtrend)

Current 4,630Won52-week high 6,24052-week low 4,410

1-month return1.0Point

1m -7.95% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral기업설명회(IR)개최2026-03-30
Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-03-23
Neutral정기주주총회결과2026-03-20